PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 1,024 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 1,024 shares of PTC Therapeutics stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $78.70, for a total value of $80,588.80. Following the completion of the transaction, the insider owned 80,141 shares of the company’s stock, valued at approximately $6,307,096.70. This represents a 1.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Pauwels also recently made the following trade(s):

• On Friday, January 9th, Eric Pauwels sold 1,722 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.41, for a total value of $133,300.02.
• On Thursday, January 8th, Eric Pauwels sold 4,602 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.50, for a total transaction of $352,053.00.
• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $104,752.96.
• On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $137,663.55.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total transaction of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total value of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.06, for a total value of $240,342.12.

PTC Therapeutics Price Performance

Shares of PTCT stock opened at $77.59 on Tuesday. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The firm has a market cap of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49. The company has a 50-day moving average of $76.81 and a two-hundred day moving average of $63.11.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. During the same period in the prior year, the firm earned ($1.39) earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. Sell-side analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Institutional Investors Weigh In On PTC Therapeutics

Several large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in shares of PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares during the period. Optiver Holding B.V. grew its position in PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares during the last quarter. Comerica Bank grew its position in PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the last quarter. IFP Advisors Inc increased its stake in PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 310 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of PTC Therapeutics by 42.1% in the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 295 shares during the last quarter.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC provided a detailed update at the J.P. Morgan conference saying Sephience™ (sepiapterin) continues to scale — unaudited Q4 global Sephience revenue of $92.5M, unaudited 2025 total product & royalty revenue of ~ $823M (above guidance), 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth), and cash of ~$1.94B. These results and the 2026 guidance are the main bullish catalysts for the stock today. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Positive Sentiment: PTC presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available), reinforcing commercial execution and management commentary that supports the guidance and growth story. Conference Transcript
• Neutral Sentiment: Reported short interest data shows 0 shares (appears to be a data anomaly / NaN change) and a 0.0 days-to-cover — likely not meaningful to trading given the company’s volume and recent volatility. (Source: market data entry)
• Negative Sentiment: Multiple insiders disclosed open‑market sales between Jan 6–12 (CEO Matthew B. Klein, CFO Pierre Gravier, VP Mark Boulding, EVP/other officers including Eric Pauwels, Christine Utter, Lee Golden, Neil Almstead). Individual sales ranged from several dozen to several thousand shares; the CEO and other executives still retain large positions. Insider selling can create short‑term caution among investors even when shares are sold in open‑market transactions. Key filings/articles: CEO Form 4 (SEC). CEO Form 4 Eric Pauwels Form 4 (SEC). Pauwels Form 4 Media summary of CFO/CEO sales. Insider Selling Article

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PTCT. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. TD Cowen increased their target price on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Wells Fargo & Company lifted their price target on PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. The Goldman Sachs Group upped their price objective on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research report on Wednesday, November 5th. Finally, Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and raised their target price for the stock from $82.00 to $91.00 in a research report on Monday, December 1st. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $77.27.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.